Medicilon(SH:688202) 第一财经·2025-09-25 02:08Core Viewpoint - The article discusses a legal dispute between MediX (688202.SH) and Hongxu Biopharmaceutical Technology (Beijing) Co., Ltd. regarding the delayed delivery of a safety evaluation report for a new drug, resulting in a claim of approximately 159 million yuan, which is 28 times the contract amount [3][4][7]. Group 1: Legal Dispute Details - Hongxu Biopharmaceutical filed a lawsuit against MediX's subsidiary for failing to deliver a non-clinical safety evaluation report within the agreed timeframe, causing significant delays in the drug's development and loss of market opportunities [4][11]. - The contract signed in December 2020 stipulated that the report should be delivered within eight months, but it was only delivered in December 2022, over a year late [8][9]. - The lawsuit claims damages based on the initial payment of 5.0184 million yuan, with penalties calculated at a daily rate of 0.05% for the delay, totaling approximately 1.59 billion yuan in claims [7][11]. Group 2: Impact on Companies - The delay in the safety evaluation report has severely impacted Hongxu Biopharmaceutical's strategic and commercial plans, as the new drug was expected to be among the top contenders in the market [11]. - MediX's subsidiary, MediX Puya, has been a significant revenue contributor, accounting for approximately 41.81% of MediX's total revenue in 2024, despite reporting a net loss of 77.63 million yuan [12]. - MediX has experienced a decline in overall performance, with net profits dropping significantly in 2023 and 2024 due to increased competition and economic factors [12].